EssilorLuxottica FY25 Profit Down, Revenues Rise; Sees Growth Ahead

EssilorLuxottica reported FY2025 revenue of €28.49bn, up 7.5% year-on-year (11.2% at constant FX) with Q4 revenue up 18.4% and double-digit growth across North America, EMEA and Asia-Pacific. Group net profit fell 1.9% to €2.32bn (EPS €4.98 vs €5.13), while adjusted group net profit rose to €3.16bn and adjusted operating profit increased 1% to €4.46bn (adjusted operating margin 16.0%, down 70bps at constant FX) despite a 2% decline in reported operating profit to €3.38bn. Management flagged headwinds from US tariffs and AI-glasses but reiterated a five-year outlook targeting solid revenue growth with broadly aligned adjusted operating profit, and the board will propose a €4.00/share dividend payable from June 3.

Analysis

Market structure: EssilorLuxottica (OTC:ESLOY / ENXTPA:EL) shows robust top-line — €28.49bn, +11.2% at constant FX — with Q4 double-digit regional growth, favoring scale leaders (lens-makers, branded retail, optical lab networks). Winners: Hoya, Carl Zeiss Meditec, in-store retail chains and suppliers that can absorb tariff pass-through; losers: smaller players (e.g., Safilo SALO.MI), low-margin fast-fashion eyewear, and US importers hit by tariffs that compressed adjusted operating margin ~70 bps. Cross-asset: expect modest spread widening for HY corporate bonds of smaller eyewear firms, EUR sensitivity to sentiment, and higher implied equity vols in short-term options around tariff/earnings headlines.

Risk assessment: tail risks include harsher US tariffs (negative shock to margins >100bps), medtech regulatory reclassification for AI-glasses, and failed technology commercialization; these are low probability but >€0.5–1bn EBITDA impact over 12 months. Time horizons: immediate (days) — earnings/dividend and tariff headlines will swing price; short-term (3–12 months) — margin trajectory tied to tariff remediation and cost actions; long-term (3–5 years) — medtech transformation could re-rate multiples if execution succeeds. Hidden dependencies: concentrated US revenue exposure, supplier footprints in Asia, and a high headline dividend (~€4 vs EPS €4.98) that could crowd out R&D/CapEx.

Trade implications: establish a tactical overweight in ESLOY (2–3% portfolio) on weakness >8% from current levels, target 15–25% total return in 12 months, stop-loss 10%. Implement a relative-value pair: long ESLOY (1.5%) / short Safilo (SALO.MI, 1.5%) expecting scale-driven margin outperformance over 6–12 months. Use options to express asymmetric upside: buy a 12–18 month 20–30% OTM call spread sized 0.5–1% portfolio to limit cash outlay while capturing medtech re-rating. Rotate sector exposure toward optical components/medtech (add HOYA 7741.T or Carl Zeiss Meditec ETR:AFXGN, 1–2% each) and trim low-margin apparel/accessory retail exposures by 2–4%.

Contrarian angles: the market fixates on margin compression from tariffs and AI-glasses costs, but underlying +11.2% organic revenue growth and recurring cash flow suggest management can sustain dividend and fund medtech capex or tuck-in M&A — a catalyst that could lift multiples 10–20% if executed. Conversely, consensus underestimates the dividend’s signalling risk: a sustained high payout (~>70% EPS) could force equity-funded deals or slower innovation. Historical parallels: prior tariff episodes resolved within 6–12 months with limited permanent share loss, implying a tactical buying window if tariffs de-escalate; unintended consequence — tariffs could accelerate reshoring and benefit US-based suppliers sooner than expected.

Key Decisions for Investors

• Establish a 2–3% long position in EssilorLuxottica (OTC:ESLOY / ENXTPA:EL) on any pullback >8% intraday from current levels; target 15–25% total return over 12 months and set a hard stop-loss at 10%.
• Initiate a market-neutral pair: long ESLOY (1.5% portfolio) and short Safilo (SALO.MI, 1.5%) to capture scale/margin divergence over a 6–12 month horizon; close if relative performance reverses by >15%.
• Buy a 12–18 month call spread on ESLOY sized 0.5–1% portfolio (buy 20–30% OTM LEAP, sell 40–50% OTM to finance) to express upside from successful medtech commercialization while capping premium.
• Overweight optical components/medtech suppliers: add 1–2% positions in HOYA (TYO:7741) and Carl Zeiss Meditec (ETR:AFXGN) to play upstream margin capture; trim 2–4% from low-margin fashion/accessory retail names.
• Conditional action: if US tariffs are fully rolled back within 90 days, add incremental 1–2% to ESLOY and unwind short Safilo; if tariffs escalate or regulatory classification of AI-glasses triggers >100bps margin hit, reduce ESLOY exposure to <1% immediately.